AR003662A1 - Una formulacion de liberacion continua de 11-[4-[2-(2-hidroxietoxi)etil]-1- piperazinil] dibenzo-[b, f][1, 4]tiazepina; usos en la fabricacion de medicamentos y un proceso para preparar dicha formulacion - Google Patents

Una formulacion de liberacion continua de 11-[4-[2-(2-hidroxietoxi)etil]-1- piperazinil] dibenzo-[b, f][1, 4]tiazepina; usos en la fabricacion de medicamentos y un proceso para preparar dicha formulacion

Info

Publication number
AR003662A1
AR003662A1 ARP970102352A ARP970102352A AR003662A1 AR 003662 A1 AR003662 A1 AR 003662A1 AR P970102352 A ARP970102352 A AR P970102352A AR P970102352 A ARP970102352 A AR P970102352A AR 003662 A1 AR003662 A1 AR 003662A1
Authority
AR
Argentina
Prior art keywords
formulation
thiazepine
dibenzo
piperazinyl
continuous release
Prior art date
Application number
ARP970102352A
Other languages
English (en)
Spanish (es)
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10794541&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR003662(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of AR003662A1 publication Critical patent/AR003662A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
ARP970102352A 1996-05-31 1997-05-30 Una formulacion de liberacion continua de 11-[4-[2-(2-hidroxietoxi)etil]-1- piperazinil] dibenzo-[b, f][1, 4]tiazepina; usos en la fabricacion de medicamentos y un proceso para preparar dicha formulacion AR003662A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9611328.7A GB9611328D0 (en) 1996-05-31 1996-05-31 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
AR003662A1 true AR003662A1 (es) 1998-09-09

Family

ID=10794541

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970102352A AR003662A1 (es) 1996-05-31 1997-05-30 Una formulacion de liberacion continua de 11-[4-[2-(2-hidroxietoxi)etil]-1- piperazinil] dibenzo-[b, f][1, 4]tiazepina; usos en la fabricacion de medicamentos y un proceso para preparar dicha formulacion

Country Status (31)

Country Link
EP (1) EP0907364B1 (enExample)
JP (5) JP2000511170A (enExample)
CN (3) CN101006985A (enExample)
AR (1) AR003662A1 (enExample)
AT (1) ATE222105T1 (enExample)
AU (1) AU727219B2 (enExample)
BR (1) BR9709271A (enExample)
CA (1) CA2251944C (enExample)
CZ (1) CZ293760B6 (enExample)
DE (1) DE69714739T2 (enExample)
DK (1) DK0907364T3 (enExample)
EG (1) EG24118A (enExample)
ES (1) ES2182079T3 (enExample)
GB (2) GB9611328D0 (enExample)
HR (1) HRP970299B1 (enExample)
HU (1) HU225152B1 (enExample)
ID (1) ID18352A (enExample)
IL (1) IL127222A (enExample)
MY (1) MY120120A (enExample)
NO (1) NO327801B1 (enExample)
NZ (1) NZ332198A (enExample)
PL (1) PL189887B1 (enExample)
PT (1) PT907364E (enExample)
RU (1) RU2201754C2 (enExample)
SI (1) SI0907364T1 (enExample)
SK (1) SK284131B6 (enExample)
TR (1) TR199802483T2 (enExample)
TW (1) TW550076B (enExample)
UA (1) UA50772C2 (enExample)
WO (1) WO1997045124A1 (enExample)
ZA (1) ZA974735B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation
SE0003126D0 (sv) * 2000-09-05 2000-09-05 Astrazeneca Ab Method of treatment
MXPA03007337A (es) 2001-02-15 2005-03-07 King Pharmaceuticals Inc Composicion farmaceutica y de hormona tiroidea estabilizada y metodo de preparacion de la misma.
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
WO2003039516A1 (en) * 2001-11-07 2003-05-15 Fujisawa Pharmaceuticla Co., Ltd. Method for improving dissolution of poorly dispersible medicaments
TW200735878A (en) * 2005-11-18 2007-10-01 Astrazeneca Ab Pharmaceutical compositions
EP1976487A2 (en) 2006-01-25 2008-10-08 Astron Research Limited Sustained release dosage form of phenothiazine derivatives containing channelizer
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
ATE480227T1 (de) 2007-02-14 2010-09-15 Lesvi Laboratorios Sl Pharmazeutische zusammensetzungen mit quetiapinfumarat
EP2131817A2 (en) 2007-03-09 2009-12-16 Synthon B.V. Pharmaceutical composition of quetiapine fumarate
US20080287418A1 (en) * 2007-05-16 2008-11-20 Astrazeneca Ab Extended Release Compositions and Methods for Their Manufacture
PL2262486T3 (pl) * 2008-08-01 2013-06-28 Krka Tovarna Zdravil D D Novo Mesto Kompozycja kwetiapiny
EP2153834A3 (en) 2008-08-07 2010-02-24 Farmaprojects, S.A. Extended release pharmaceutical compositions comprising quetiapine salts
DE102008046650A1 (de) * 2008-09-10 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Quetiapin enthaltende Retardtablette
WO2010082220A2 (en) * 2009-01-05 2010-07-22 Torrent Pharmaceuticals Limited Sustained release pharmaceutical composition of quetiapine and process for preparation thereof
WO2010089259A2 (en) 2009-02-04 2010-08-12 Woerwag R&D Gmbh Sustained release composition containing quetiapine
EP2233130A1 (en) * 2009-03-23 2010-09-29 Genepharm (Europe) Trading Limited A sustained release oral composition of an antipsychotic agent
AR076907A1 (es) * 2009-05-13 2011-07-20 Wyeth Llc Composiciones con liberacion rapida de farmaco
WO2011132008A2 (en) 2010-04-22 2011-10-27 EGIS Gyűgyszergyár Nyilvánosan Múködő Részvény társaság Controlled release pharmaceutical composition
WO2011154118A1 (en) 2010-06-07 2011-12-15 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Quetiapine prolonged-release tablets
DE102010033527A1 (de) 2010-08-05 2012-02-09 Acino Pharma Ag Quetiapin-Tabletten
TR201008261A1 (tr) 2010-10-08 2012-04-24 Sanovel İlaç San. Ve Ti̇c. A.Ş. Kontrollü salım gerçekleştiren ketiapin formülasyonları
CN102218042A (zh) * 2011-05-26 2011-10-19 青岛黄海制药有限责任公司 富马酸喹硫平组合物的缓释片剂及其制备方法
DE102011115690A1 (de) 2011-10-11 2013-04-11 Acino Pharma Ag Quetiapin enthaltende Formulierungen
CN102406606B (zh) * 2011-11-29 2013-01-23 海南美大制药有限公司 富马酸喹硫平脂质体固体制剂
DK2822541T3 (da) 2012-09-10 2019-01-02 Pharmathen Sa Farmaceutisk sammensætning omfattende et atypisk antipsykotisk middel og fremgangsmåde til fremstilling deraf
EP2848244A1 (en) 2013-09-16 2015-03-18 Yildiz Özsoy Erginer Extended release tablet formulations of quetiapine
CA2988918A1 (en) 2015-06-19 2016-12-22 Biotie Therapies, Inc. Controlled-release tozadenant formulations
CN106187873B (zh) * 2016-07-25 2019-11-05 宜春学院 一种芳胺基烷基氧类化合物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4775535A (en) * 1986-04-04 1988-10-04 Hans Lowey Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
ATE71833T1 (de) * 1986-11-03 1992-02-15 Schering Corp Labetalol tablette mit verzoegerter wirkstoffabgabe.
IE59540B1 (en) * 1987-01-09 1994-03-09 Elan Corp Sustained release capsule or tablet formulation
GB8705574D0 (en) * 1987-03-10 1987-04-15 Ici Plc Preparation of thiazepine compound
US4983398A (en) * 1987-12-21 1991-01-08 Forest Laboratories, Inc. Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
SE9003902D0 (sv) * 1990-12-07 1990-12-07 Astra Ab Solid dosage forms of a drug
IT1256651B (it) * 1992-12-11 1995-12-12 Giancarlo Santus Composizione farmaceutica a rilascio controllato in sospensione liquida
JP3116970B2 (ja) * 1991-06-12 2000-12-11 三菱東京製薬株式会社 ペミロラストカリウムの徐放性製剤
IT1256393B (it) * 1992-11-17 1995-12-04 Inverni Della Beffa Spa Forme matriciali multistrato per il rilascio controllato di principi attivi
US5393765A (en) * 1993-12-13 1995-02-28 Hoffmann-La Roche Inc. Pharmaceutical compositions with constant erosion volume for zero order controlled release
WO1995031186A1 (en) * 1994-05-13 1995-11-23 Smithkline Beecham Corporation Method and composition for increasing calcium uptake

Also Published As

Publication number Publication date
NO985539D0 (no) 1998-11-27
SK284131B6 (sk) 2004-09-08
DE69714739T2 (de) 2003-05-15
NZ332198A (en) 2000-05-26
ID18352A (id) 1998-04-02
DK0907364T3 (da) 2002-11-11
PT907364E (pt) 2002-12-31
NO327801B1 (no) 2009-09-28
JP2006152006A (ja) 2006-06-15
JP2014167026A (ja) 2014-09-11
RU2201754C2 (ru) 2003-04-10
IL127222A (en) 2001-03-19
ES2182079T3 (es) 2003-03-01
PL189887B1 (pl) 2005-10-31
ZA974735B (en) 1997-12-01
CZ388098A3 (cs) 1999-02-17
HUP9902194A2 (hu) 2000-02-28
CZ293760B6 (cs) 2004-07-14
CN1142780C (zh) 2004-03-24
MY120120A (en) 2005-09-30
GB9709761D0 (en) 1997-07-09
EG24118A (en) 2008-07-06
UA50772C2 (uk) 2002-11-15
SI0907364T1 (en) 2003-02-28
EP0907364B1 (en) 2002-08-14
GB9611328D0 (en) 1996-08-07
CN1219879A (zh) 1999-06-16
HU225152B1 (en) 2006-07-28
TR199802483T2 (xx) 1999-02-22
CA2251944C (en) 2007-04-10
CN1511532A (zh) 2004-07-14
TW550076B (en) 2003-09-01
SK163998A3 (en) 1999-05-07
JP5888549B2 (ja) 2016-03-22
PL330223A1 (en) 1999-05-10
HRP970299A2 (en) 1998-04-30
CN101006985A (zh) 2007-08-01
ATE222105T1 (de) 2002-08-15
HUP9902194A3 (en) 2000-03-28
HRP970299B1 (en) 2001-12-31
JP2007119495A (ja) 2007-05-17
EP0907364A1 (en) 1999-04-14
WO1997045124A1 (en) 1997-12-04
BR9709271A (pt) 1999-08-10
JP2012031206A (ja) 2012-02-16
AU2967597A (en) 1998-01-05
DE69714739D1 (de) 2002-09-19
CA2251944A1 (en) 1997-12-04
JP2000511170A (ja) 2000-08-29
IL127222A0 (en) 2000-06-01
AU727219B2 (en) 2000-12-07
NO985539L (no) 1998-11-27

Similar Documents

Publication Publication Date Title
AR003662A1 (es) Una formulacion de liberacion continua de 11-[4-[2-(2-hidroxietoxi)etil]-1- piperazinil] dibenzo-[b, f][1, 4]tiazepina; usos en la fabricacion de medicamentos y un proceso para preparar dicha formulacion
HUP0000558A3 (en) Use of active d vitamin analogues for producing pharmaceutical composition for the treatment of prostatic diseases
IL161833A0 (en) Pharmaceutical compositions and usethereof for thetreatment of psychotic diseases
ITRM940730A0 (it) Protesi dinamica in duplice strato per il trattamento chirurgico dell'ernia inguinale
ES2187201T3 (es) Empleo de esteroles y de esterolesteres a nanoescala.
EE04021B1 (et) 7a-( -aminoalküül)östratrieenid, nende valmistamise meetod, 7a-( -aminoalküül)östratrieene sisaldavad farmatseutilised preparaadid ja nende kasutamine ravimite valmistamiseks
MA26901A1 (fr) Nouvelle composition pharmaceutique
AR015524A1 (es) FORMULACIoN ESTABLE DE SOLUCIoN DE OXIPLATINO, SU USO PARA LA MANUFACTURA DE UN MEDICAMENTO, PROCESO PARA SU PREPARACIoN, PRODUCTO FARMACÉUTICO QUE LA CONTIENE Y UN MÉTODO PARA ESTABILIZAR UNA SOLUCIoN DE OXALIPLATINO.
PL329940A1 (en) Compositions for once-a-day administration for use in treating diseases involving mediator effect of cyclooxygenase-2
BG106509A (en) Preparative form
BR9704203A (pt) Processo para produzir reína e derivados de reína e difenilcetona derivado composição farmacêutica e preparação cosmética
BR9404225A (pt) Formulação de substância ativa, aplicação, composições, medicamentos e processo para a preparação das formulações
FI982689L (fi) 2-fenyyli-1,2-bentsoisoselenatsol-3(2H)-onin käyttö Alzheimerin taudin käsittelyyn tarkoiettujen farmaseuttisten valmisteiden valmistukseen
HU9501925D0 (en) Ortho-amine-substituted benzoyl-guanidine derivatives, process for producing them their pharmaceutical or diagnostical use, and pharmaceutical compositions containing them
AU5053296A (en) Pharmaceutical agents for the treatment of Alzheimer's disease
MA23663A1 (fr) Procede de preparation de formulations pharmaceutiques
BR9713044A (pt) Composto, uso de um composto, processo para sua preparação,e, formulação farmacêutica.
CO4970832A1 (es) Nuevas formulaciones y procesos para su fabricacion
BR0111055A (pt) Formulação farmacêutica, e, processo para a preparação e uso da mesma
DE60018301D1 (de) Neue pyrimidin-2,4,6-trion-derivate, verfahren zu ihrer herstellung und pharmazeutische mittel die diese enthalten
NO985807D0 (no) Transdermale systemer inneholdende 2 aktive ingredienser i separate seksjoner, deres fremstillingsprosess og deres anvendelse som medikament
BR9600217A (pt) 4-aminobenzoilguanidinas processo para a preparação de seus derivados processo para a produção de formulações farmacêuticas formulação farmacêutica e uso
ATE215941T1 (de) Isoflavonderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
ITRM920408A0 (it) Colture di tessuto di mucosa congiuntivale differenziata, procedimentoper la loro preparazione e supporti per il loro uso.
BR9611488A (pt) Estereoisômero 3r-3'r puro de zeaxantina para o tratamento da degeneração macular em seres humanos

Legal Events

Date Code Title Description
FG Grant, registration